Neutrophil Elastase, Native Protein

Neutrophil Elastase protein

For Research Use Only. Not for use in diagnostic procedures.

Human

> 95% pure

Supplied in lyophilized form. After initial centrifugation, we suggest the addition of 50 mM Na Acetate, pH 5.5, with 150 mM NaCl to the original volume, followed by gentle swirling and/or vortexing to ensure adequate homogenization.

Store at -20 degree C.

Small volumes of ELANE native protein vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Proteases; Inhibitors; & Enzymes

28,518 Da[Similar Products]

elastase, neutrophil expressed

neutrophil elastase

Neutrophil elastase

ELA2; HLE  [Similar Products]

Elastases form a subfamily of serine proteases that hydrolyze many proteins in addition to elastin. Humans have six elastase genes which encode structurally similar proteins. The encoded preproprotein is proteolytically processed to generate the active protease. Following activation, this protease hydrolyzes proteins within specialized neutrophil lysosomes, called azurophil granules, as well as proteins of the extracellular matrix. The enzyme may play a role in degenerative and inflammatory diseases through proteolysis of collagen-IV and elastin. This protein also degrades the outer membrane protein A (OmpA) of E. coli as well as the virulence factors of such bacteria as Shigella, Salmonella and Yersinia. Mutations in this gene are associated with cyclic neutropenia and severe congenital neutropenia (SCN). This gene is present in a gene cluster on chromosome 19. [provided by RefSeq, Jan 2016]

ELANE: Modifies the functions of natural killer cells, monocytes and granulocytes. Inhibits C5a-dependent neutrophil enzyme release and chemotaxis. Defects in ELANE are a cause of cyclic haematopoiesis (CH); also known as cyclic neutropenia. CH is an autosomal dominant disease in which blood-cell production from the bone marrow oscillates with 21-day periodicity. Circulating neutrophils vary between almost normal numbers and zero. During intervals of neutropenia, affected individuals are at risk for opportunistic infection. Monocytes, platelets, lymphocytes and reticulocytes also cycle with the same frequency. Defects in ELANE are the cause of neutropenia severe congenital autosomal dominant type 1 (SCN1). SCN1 is a disorder of hematopoiesis characterized by a maturation arrest of granulopoiesis at the level of promyelocytes with peripheral blood absolute neutrophil counts below 0.5 x 10(9)/l and early onset of severe bacterial infections. Belongs to the peptidase S1 family. Elastase subfamily.

Protein type: Cell cycle regulation; Cell surface; EC 3.4.21.37; Motility/polarity/chemotaxis; Protease

Chromosomal Location of Human Ortholog: 19p13.3

Cellular Component: cell surface; cytoplasm; extracellular region; extracellular space; secretory granule; transcriptional repressor complex

Molecular Function: cytokine binding; endopeptidase activity; heparin binding; peptidase activity; protease binding; protein binding; serine-type endopeptidase activity

Biological Process: acute inflammatory response to antigenic stimulus; defense response to bacterium; extracellular matrix disassembly; negative regulation of chemokine biosynthetic process; negative regulation of interleukin-8 biosynthetic process; negative regulation of transcription from RNA polymerase II promoter; phagocytosis; positive regulation of interleukin-8 biosynthetic process; positive regulation of smooth muscle cell proliferation; proteolysis; response to UV

Disease: Cyclic Neutropenia; Neutropenia, Severe Congenital, 1, Autosomal Dominant

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.